CCK(B) antagonists protect against some aspects of the ethanol withdrawal syndrome

Pharmacology Biochemistry and Behavior

Volumn 59, Issue 4, 1998, Pages 967-973

  Wilson, J ^a   Little, H J ^b  

^a School of Medical Sciences   (United Kingdom)

^b DURHAM UNIVERSITY   (United Kingdom)

Author keywords

CCK; Ethanol; Withdrawal syndrome

Indexed keywords

ALCOHOL; B ALANINE N[1A METHYL N[(TRICYCLO(3.3.1.1 3.7) DEC 2 YLOXY)CARBONYL]TRYPTOPHYL]3(PHENYLMETHYL)1 DEOXY1 (METHYLAMINO) GLUCITOL; CAM 1481; CAM 1988; CHOLECYSTOKININ A RECEPTOR ANTAGONIST; CHOLECYSTOKININ B RECEPTOR ANTAGONIST; PD 135158; UNCLASSIFIED DRUG;

ALCOHOL WITHDRAWAL; ALCOHOLISM; ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CONVULSION; DOSE RESPONSE; DRUG MECHANISM; DRUG RECEPTOR BINDING; LATENT PERIOD; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BLOCKING; SEIZURE; SUBCUTANEOUS DRUG ADMINISTRATION;

ACOUSTIC STIMULATION; ALCOHOLISM; ANIMALS; ANTI-ANXIETY AGENTS; BEHAVIOR, ANIMAL; CENTRAL NERVOUS SYSTEM DEPRESSANTS; DIPEPTIDES; ETHANOL; EXCITATORY AMINO ACID AGONISTS; HANDLING (PSYCHOLOGY); INDOLES; MALE; MEGLUMINE; MICE; MICE, INBRED STRAINS; N-METHYLASPARTATE; RECEPTORS, CHOLECYSTOKININ; SEIZURES; SUBSTANCE WITHDRAWAL SYNDROME;

ANIMALIA;

EID: 0031808733     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-3057(97)00536-4     Document Type: Article

References (23)

1. B antagonist, CI988, decrease hyperexcitability in hippocampal slices during ethanol withdrawal. Br. J. Pharmacol. 117:1996;29P.
2. Brown C. G. The alcohol withdrawal syndrome. Ann. Emerg. Med. 11:1982;276-280.
3. 125I-Bolton-Hunter labelled cholecystokinin binding in human brain. Neuropeptides. 11:1988;73-76.
4. Derrien M., McCort-Tranchepain I., Ducos B., Durieux C., Roques B. P. Heterogeneity of CCK-B receptors involved in animal models of anxiety. Pharmacol. Biochem. Behav. 49:1994;133-141.
5. Dourish C. T., Hawley D., Iversen S. D. Enhancement of morphine analgesia and prevention of morphine tolerance in the rat by the cholecystokinin antagonist L-364,718. Eur. J. Pharmacol. 147:1988;469-472.
6. 4 binding sites in mouse and rat brain. Neuropeptides. 12:1988;141-148.
7. 3H]SNF 8702 Mol. Pharmacol. 41:1992;1089-1095.
8. Goldstein D. B., Pal N. Alcohol dependence produced in mice by inhalation of ethanol. Grading the withdrawal reaction Science. 172:1971;288-290.
9. Green A. R., Davies E. M., Whittington M. A., Little H. J., Cross A. J. Action of chlormethiazole in a model of ethanol withdrawal. Psychopharmacology (Berlin). 102:1990;239-242.
10. Harro J., Wahlström G., Oreland L. Cholecystokinin receptor binding after long-term ethanol treatment in rats. Alcohol Alcohol. 29:1994;575-581.
11. Hughes J., Boden P., Costall B., Domeney A., Kelly M., Horwell D. C., Hunter D. C., Pinnock R. D., Woodruff G. N. Development of a class of selective cholecystokinin type B antagonists having potent anxiolytic activity. Proc. Natl. Acad. Sci. USA. 87:1990;6728-6732.
12. Lavigne G. J., Hargreaves K. M., Schmidt R. D., Dionne R. A. Proglumide potentiates morphine analgesia for acute postsurgical pain. Clin. Pharmacol. Ther. 45:1989;666-673.
13. Lieber C. S., Decarli L. M. Liquid diet technique of ethanol administration. 1989 update Alcohol Alcohol. 24:1989;117-121.
14. Meddis R. Statistics using ranks. A unified approach. Basil Blackwell:1984;Blackwell, Oxford.
15. Ravard S., Dourish C. T. Cholecystokinin and anxiety. Trends Pharmacol. Sci. 11:1990;271-273.
16. Rodriquez M., Lignon M. F., Galas M. C., Amblard M., Martinez J. Cyclic cholecystokinin analogues that are highly selective for rat and guinea pig central cholecystokinin receptors. Mol. Pharmacol. 38:1990;333-341.
17. Singh L., Oles R. J., Vass C. A., Woodruff G. N. A slow intravenous infusion of N-methyl-DL-aspartate as a seizure model in the mouse. J. Neurosci. Methods. 37:1991;227-232.
18. B receptor antagonist, CI-988. Br. J. Pharmacol. 105:1992;8-10.
19. Victor M., Adams K. D. The effect of alcohol on the nervous system. Res. Publ. Assoc. Nerv. Ment. Dis. 32:1953;526-573.
20. Watson W. P., Little H. J. Identification of distinct components, with different time courses, of the changes in response to convulsive stimuli during ethanol withdrawal. J. Pharmacol. Exp. Ther. 272:1995;876-884.
21. Whittington M. A., Lambert J. D. C., Little H. J. Increased NMDA receptor and calcium channel activity underlying ethanol withdrawal hyperexcitability. Alcohol Alcohol. 30:1995;105-114.
22. Williams J. A., Gryson K. A., McChesney D. J. Brain CCK receptors. Species differences in regional distribution and selectivity Peptides. 7:1986;293-296.
23. B antagonists reduce signs of anxiety-related behaviour in the elevated plus maze during withdrawal from chronic ethanol treatment. Br. J. Pharmacol. 117:1996;28P.